Table 2.
Experimental Targets in AML CARs.
| Target Name | Normal Tissue Distribution | Expression on LSCs | Phase of Development |
|---|---|---|---|
| CD7 | activated T-cells, NK cells, lymphoid and myeloid progenitors | Yes | Phase I/II clinical trial |
| CD33 | myeloid cells, myeloid progenitors, Kupffer cells | Yes | Phase I/II clinical trial |
| CD38 | plasma cells, NK cells, B-cells, HSCs (low) | No | Phase I/II clinical trial |
| CD44v6 | activated T-cells, monocytes, keratinocytes | No | Phase I/II clinical trial |
| CD70 | dendritic cells, B-cells | Yes | Phase I/II clinical trial |
| CD117 | HSCs, myeloid progenitors, erythroid progenitors | No | Preclinical |
| CD123 | myeloid cells, myeloid progenitors | Yes | Phase II/III clinical trial |
| CD276 (B7-H3) | Antigen presenting cells, HSCs (low) | No | Phase I clinical trial |
| CLL-1 | myeloid cells, myeloid progenitors | Yes | Phase I/II clinical trial |
| FLT3 | HSCs | No | Phase I clinical trial |
| FRb | myeloid cells, HSCs (low) | No | Preclinical |
| GM-CSF (CD116) | myeloid cells | No | Preclinical |
| ILT3 (LILRB4) | myeloid antigen presenting cells | No | Phase I/II clinical trial |
| NKG2D | NK cells, γδ T-cells, CD8+ T-cells | No | Phase I/II clinical trial |
| Siglec-6 | B-cells, mast cells, placenta | Yes | Preclinical |
| TIM3 | T-cells, myeloid cells, NK cells | Yes | Preclinical |
CAR = chimeric antigen receptor; AML = acute myeloid leukemia; CD = cluster of differentiation; CLL-1 = C-type lectin-like molecule-1; FLT3 = FMS related receptor tyrosine kinase 3; FRb = folate receptor b; HSC = hematopoietic stem cell; GM-CSF = granulocyte-macrophage colony-stimulated factor; ILT3 = Ig-like transcript 3; LSC = leukemic stem cell; NKG2D = natural killer group 2 member D; TIM3 = T-cell immunoglobulin and mucin domain-containing protein 3; Siglec-6 = sialic acid binding Ig-like lectin 6.